[Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
BACKGROUND
In industrialised countries the incidence of type 2 diabetes-associated end stage renal disease has doubled over the last ten years. It is important to lower the blood pressure to inhibit progression of renal failure and to prevent micro- and macrovascular disease in these patients. There is an ongoing discussion on what should be the drug of choice.


METHODS
We discuss the results from three landmark studies, recently published, on the use of angiotensin II antagonists in patients with type 2 diabetics and nephropathy.


CONCLUSIONS
All three studies found a renoprotective effect of angiotensin II antagonists that could not be explained by the effect on the blood pressure alone. Blockade of the renin angiotensin system with angiotensin II antagonist should be the basis of treatment in type 2 diabetic nephropathy.
Os
Ingrid
I
Nyremedisinsk avdeling Ullevål universitetssykehus 0407 Oslo. ingrid.os@ioks.uio.no
Stenehjem
Aud
A
Høieggen
Aud
A
Draganov
Branimir
B
Jenssen
Trond
T
Holdaas
Hallvard
H
D017311:Amlodipine / Q000627:therapeutic use; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D000804:Angiotensin II; D017311:Amlodipine; D019808:Losartan